Targeted Therapy Selection Based on Tumor Tissue Kinase Activity Profiles for Patients With Advanced Solid Malignancies, an Exploratory Study

NCT01190241 · clinicaltrials.gov ↗

NA

Phase

TERMINATED

Status

45

Enrollment

OTHER

Sponsor class

Conditions

Advanced Solid Tumors
Inoperable
Metastasis

Interventions

DRUG: desatinib or sunitinib or erlotinib or everolimus or lapatinib or sorafenib

Sponsor

Amsterdam UMC, location VUmc

Collaborators

[object Object]